Limits...
Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus

Therapeutic effect of CEA-SARS-derived epitopes on tumor establishment. BALB/c mice were inoculated with CT26/CEA cells on day 0. Four days later, the mice were fed with pCEA- and pCEA-SARS-transformed S. typhimurium once per week (5 mice/group), and the subsequent tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298716&req=5

Figure 4: Therapeutic effect of CEA-SARS-derived epitopes on tumor establishment. BALB/c mice were inoculated with CT26/CEA cells on day 0. Four days later, the mice were fed with pCEA- and pCEA-SARS-transformed S. typhimurium once per week (5 mice/group), and the subsequent tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).

Mentions: Regarding the therapeutic effects of the vaccines, mice were inoculated with 1 × 105 CT26/CEA and 4 days later orally immunized with 1 × 108 S. typhimurium transformed with pCEA, or pCEA-SARS-CoV in 20 μl PBS, while the negative control group was fed with 20 μl PBS. While therapy with pCEA was not able to induce responses to reduce the growth of tumors in comparison with the control group, mice in the CEA-SARS-CoV group exhibited significantly less tumor growth, indicating that the SARS fragment provided adequate protection against CT26/CEA (Figure 4, p < 0.05 in comparison with the control and the pCEA group).


Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

Therapeutic effect of CEA-SARS-derived epitopes on tumor establishment. BALB/c mice were inoculated with CT26/CEA cells on day 0. Four days later, the mice were fed with pCEA- and pCEA-SARS-transformed S. typhimurium once per week (5 mice/group), and the subsequent tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298716&req=5

Figure 4: Therapeutic effect of CEA-SARS-derived epitopes on tumor establishment. BALB/c mice were inoculated with CT26/CEA cells on day 0. Four days later, the mice were fed with pCEA- and pCEA-SARS-transformed S. typhimurium once per week (5 mice/group), and the subsequent tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
Mentions: Regarding the therapeutic effects of the vaccines, mice were inoculated with 1 × 105 CT26/CEA and 4 days later orally immunized with 1 × 108 S. typhimurium transformed with pCEA, or pCEA-SARS-CoV in 20 μl PBS, while the negative control group was fed with 20 μl PBS. While therapy with pCEA was not able to induce responses to reduce the growth of tumors in comparison with the control group, mice in the CEA-SARS-CoV group exhibited significantly less tumor growth, indicating that the SARS fragment provided adequate protection against CT26/CEA (Figure 4, p < 0.05 in comparison with the control and the pCEA group).

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus